CAS 1607837-31-9

Formule : C21H23ClN6O

InChI : InChI=1S/C21H23ClN6O/c1-27-16-3-2-13(10-14(16)11-26-27)15-12-25-19(23)17(22)18(15)28-8-5-21(6-9-28)4-7-24-20(21)29/h2-3,10-12H,4-9H2,1H3,(H2,23,25)(H,24,29)

Code InChI : VPJXPDLMACOGIZ-UHFFFAOYSA-N

SMILES : CN1C2=C(C=C(C=C2)C3=CN=C(C(=C3N4CCC5(CCNC5=O)CC4)Cl)N)C=N1

CCT-251921

CAS : 1607837-31-9

Formule : C₂₁H₂₃ClN₆O

Masse moléculaire : 410.8999

Ref: IN-DA001VCJ

CCT-251921

CAS : 1607837-31-9

CCT-251921

Formule : C₂₁H₂₃ClN₆O

Degré de pureté : ≥95%

Masse moléculaire : 410.9

Ref: 54-BUP14305

CCT-251921

CAS : 1607837-31-9

8-(2-Amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one

Formule : C₂₁H₂₃ClN₆O

Degré de pureté : 99%

Masse moléculaire : 410.9

Ref: IN-DG748583

CCT-251921

CAS : 1607837-31-9

CCT-251921 is a molecule that inhibits the activity of cyclin-dependent kinases (CDKs) 4 and 6. It has been shown to inhibit inflammatory bowel disease in animal models, with no observed side effects. The compound also exhibits cytostatic activity against tumor cells by inhibiting β-catenin signaling. CCT-251921 has been shown to have no effect on healthy cells, but does cause cell death in cancer cells due to its ability to inhibit the transcriptional regulation of β-catenin. In addition, CCT-251921 has shown anti-inflammatory properties in clinical trials for autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

Formule : C₂₁H₂₃ClN₆O

Degré de pureté : Min. 95%

Masse moléculaire : 410.9 g/mol

Ref: 3D-HPC83731

CCT-251921

CAS : 1607837-31-9

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).

Formule : C₂₁H₂₃ClN₆O

Degré de pureté : 99.07%

Couleur et forme : Solid

Masse moléculaire : 410.9

Ref: TM-T14901